Plain-English translation of NCT06224387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing a new oral medication called CTS2190 in people with advanced solid tumors who have not responded to or cannot tolerate standard cancer treatments. The trial has two parts: the first part tests increasing doses to find the right dose and monitor safety, and the second part expands testing in specific cancer types. If you tolerate the medication well, you may continue taking it as long as your cancer doesn't progress.
Many patients with advanced cancers run out of effective treatment options or cannot tolerate standard therapies. This medication is being studied to see if it can offer a new treatment path for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily at home, starting with a screening visit that includes blood tests and imaging to confirm your eligibility. Depending on which part of the trial you join, you may be in a group testing a specific dose, and your dose may be adjusted based on how well you tolerate it. You'll have regular follow-up visits (typically every few weeks) for blood work, imaging scans, and check-ins about side effects. You can continue taking the medication as long as it's helping and you're tolerating it well, or until the study ends—potentially for up to 48 weeks or longer.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China